73 related articles for article (PubMed ID: 8593750)
1. Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.
Guise CP; Mowday AM; Ashoorzadeh A; Yuan R; Lin WH; Wu DH; Smaill JB; Patterson AV; Ding K
Chin J Cancer; 2014 Feb; 33(2):80-6. PubMed ID: 23845143
[TBL] [Abstract][Full Text] [Related]
2. Clinical Advances of Hypoxia-Activated Prodrugs in Combination With Radiation Therapy.
Mistry IN; Thomas M; Calder EDD; Conway SJ; Hammond EM
Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1183-1196. PubMed ID: 28721903
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia and its therapeutic possibilities in paediatric cancers.
Bernauer C; Man YKS; Chisholm JC; Lepicard EY; Robinson SP; Shipley JM
Br J Cancer; 2021 Feb; 124(3):539-551. PubMed ID: 33106581
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and evaluation of molecularly targeted hypoxia-activated prodrugs.
O'Connor LJ; Cazares-Körner C; Saha J; Evans CN; Stratford MR; Hammond EM; Conway SJ
Nat Protoc; 2016 Apr; 11(4):781-94. PubMed ID: 27010756
[TBL] [Abstract][Full Text] [Related]
5. Design of optimized hypoxia-activated prodrugs using pharmacokinetic/pharmacodynamic modeling.
Foehrenbacher A; Secomb TW; Wilson WR; Hicks KO
Front Oncol; 2013 Dec; 3():314. PubMed ID: 24409417
[TBL] [Abstract][Full Text] [Related]
6. The meaning, measurement and modification of hypoxia in the laboratory and the clinic.
Hammond EM; Asselin MC; Forster D; O'Connor JP; Senra JM; Williams KJ
Clin Oncol (R Coll Radiol); 2014 May; 26(5):277-88. PubMed ID: 24602562
[TBL] [Abstract][Full Text] [Related]
7. Recent Development of Transition Metal Complexes as Chemotherapeutic Hypoxia Activated Prodrug (HAP).
Jagathesan K; Roy S
ChemMedChem; 2024 Apr; ():e202400127. PubMed ID: 38634306
[TBL] [Abstract][Full Text] [Related]
8. Antibody-Based Imaging of Bioreductive Prodrug Release in Hypoxia.
Tosun Ç; Wallabregue ALD; Mallerman M; Phillips SE; Edwards CM; Conway SJ; Hammond EM
JACS Au; 2023 Nov; 3(11):3237-3246. PubMed ID: 38034969
[TBL] [Abstract][Full Text] [Related]
9. Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs).
Denny WA; Wilson WR
Cancer Metastasis Rev; 1993 Jun; 12(2):135-51. PubMed ID: 8375017
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-activated prodrugs in cancer therapy: progress to the clinic.
Denny WA
Future Oncol; 2010 Mar; 6(3):419-28. PubMed ID: 20222798
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia-activated prodrugs as antitumour agents: strategies for maximizing tumour cell killing.
Wilson WR; Pruijn FB
Clin Exp Pharmacol Physiol; 1995 Nov; 22(11):881-5. PubMed ID: 8593750
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs.
Lash CJ; Li AE; Rutland M; Baguley BC; Zwi LJ; Wilson WR
Br J Cancer; 1998 Aug; 78(4):439-45. PubMed ID: 9716024
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and metabolism of the nitrogen mustard bioreductive drug 5.
Kestell P; Pruijn FB; Siim BG; Palmer BD; Wilson WR
Cancer Chemother Pharmacol; 2000; 46(5):365-74. PubMed ID: 11127940
[TBL] [Abstract][Full Text] [Related]
14. Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia.
Guise CP; Wang AT; Theil A; Bridewell DJ; Wilson WR; Patterson AV
Biochem Pharmacol; 2007 Sep; 74(6):810-20. PubMed ID: 17645874
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
